News On ATyr Pharma Inc. (LIFE) Now Under ATYR
News On ATyr Pharma Inc. (LIFE) Now Under ATYR
ATyr Pharma(LIFE.US) Director Buys US$87,500 in Common Stock
$aTyr Pharma(LIFE.US)$ Director COUGHLIN TIMOTHY purchased 50,000 shares of common stock on May 30, 2024 at an average price of $1.75 for a total value of $87,500.Source: Announcement What is statemen
ATyr Pharma(LIFE.US) Officer Buys US$8,950 in Common Stock
$aTyr Pharma(LIFE.US)$ Officer Broadfoot Jill Marie purchased 5,000 shares of common stock on May 31, 2024 at an average price of $1.79 for a total value of $8,950.Source: Announcement What is stateme
ATyr Pharma(LIFE.US) Officer Buys US$36,140 in Common Stock
$aTyr Pharma(LIFE.US)$ Officer Shukla Sanjay purchased 20,000 shares of common stock on May 31, 2024 at an average price of $1.807 for a total value of $36,140.Source: Announcement What is statement o
Express News | aTyr Pharma has announced changes in ticker details from "Life" to "aTyr" on NASDAQ stocks.
Express News | ATyr Pharma Announces Nasdaq Stock Ticker Symbol Change From “Life” to “aTyr”
ATyr Pharma Stockholders Endorse Leadership and Progress
ATyr Pharma Buy Rating: Novel Treatment's Market Potential and Financial Upside
aTyr Pharma Inc.: Jonestrading assumes coverage is a buy rating; target price is $22
aTyr Pharma Inc.: Jonestrading assumes coverage is a buy rating; target price is $22
Express News | ATyr Pharma Inc : Jonestrading Assumes Coverage With Buy Rating; Target Price $22
aTyr Pharma Announces Incentive Grants Under Nasdaq Listing Rule 5635 (C) (4)
aTyr Pharma Announces Incentive Grants Under Nasdaq Listing Rule 5635 (C) (4)
Express News | ATyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Analysts' Top Healthcare Picks: ATyr Pharma (LIFE), Dynavax (DVAX)
ATyr Pharma Says DSMB Recommended Ongoing Phase 3 EFZO-FIT Study Of Efzofitimod Continue Without Any Modifications
ATyr Pharma Says DSMB Recommended Ongoing Phase 3 EFZO-FIT Study Of Efzofitimod Continue Without Any Modifications
ATyr Pharma to Present at Upcoming Investor Conferences
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its pro
HC Wainwright & Co. : The ATyr Pharma (LIFE.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $35.00.
HC Wainwright & Co. : The ATyr Pharma (LIFE.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $35.00.
RBC Capital Sticks to Their Buy Rating for ATyr Pharma (LIFE)
Strong Buy Rating for ATyr Pharma as Efzofitimod Shows Promise and Financial Stability
ATyr Pharma Q1 EPS $(0.23) Beats $(0.24) Estimate, Sales $235.00K Beat $20.00K Estimate
aTyr Pharma (NASDAQ:LIFE) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 20.69 percent increase over losses of $(0.29) p
Earnings Flash (LIFE) ATYR PHARMA Reports Q1 Revenue $235,000
04:00 PM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (LIFE) ATYR PHARMA Reports Q1 Revenue $235,000